{"filing":{"accession_number":"0001104659-26-080311","cik":"0001829635","ticker":"RNAZ","company_name":"Transcode Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"tm2619681d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926080311/tm2619681d1_8k.htm"},"events":[{"id":15821,"run_id":14113,"accession_number":"0001104659-26-080311","anchor_item_number":"8.01","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses the commencement and adjournment of the 2026 Annual Meeting of Stockholders, with preliminary voting reports indicating all proposals have received necessary stockholder support for approval. While the meeting was adjourned pending Nasdaq's review of the initial listing application (specifically regarding Proposal 1 on conversion of preferred stock), the core disclosure centers on stockholder voting results and the reconvened meeting scheduled for July 20, 2026. This is material as it relates to shareholder approval of significant corporate actions, particularly the conversion of Series A and Series B Non-Voting Convertible Preferred Stock into common stock.","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13722,"accession_number":"0001104659-26-080311","item_number":"8.01","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the commencement and adjournment of the 2026 Annual Meeting of Stockholders, with preliminary voting reports indicating all proposals have received necessary stockholder support for approval. While the meeting was adjourned pending Nasdaq's review of the initial listing application (specifically regarding Proposal 1 on conversion of preferred stock), the core disclosure centers on stockholder voting results and the reconvened meeting scheduled for July 20, 2026. This is material as it relates to shareholder approval of significant corporate actions, particularly the conversion of Series A and Series B Non-Voting Convertible Preferred Stock into common stock.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:08:59.565424+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13722,"accession_number":"0001104659-26-080311","item_number":"8.01","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the commencement and adjournment of the 2026 Annual Meeting of Stockholders, with preliminary voting reports indicating all proposals have received necessary stockholder support for approval. While the meeting was adjourned pending Nasdaq's review of the initial listing application (specifically regarding Proposal 1 on conversion of preferred stock), the core disclosure centers on stockholder voting results and the reconvened meeting scheduled for July 20, 2026. This is material as it relates to shareholder approval of significant corporate actions, particularly the conversion of Series A and Series B Non-Voting Convertible Preferred Stock into common stock.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:08:59.565424+00:00","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-07-02"}]}